A phase II study evaluating pharmacokinetics and dosimetry of &lt;sup&gt;177&lt;/sup&gt;Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancer. Here, FOLH1 is linked to prostate cancer.